Polyproline-type helical-structured low-molecular weight heparin (LMWH)-taurocholate conjugate as a new angiogenesis inhibitor

International Journal of Cancer

Volumn 124, Issue 12, 2009, Pages 2755-2765

  Lee, Esak ^a   Kim, Yoo Shin ^b   Bae, Sang Mun ^b   Kim, Sang Kyoon ^a   Jin, Shunji ^a   Chung, Seung Woo ^a   Lee, Myungjin ^c   Moon, Hyun Tae ^d   Jeon, Ok Cheol ^d   Park, Rang Woon ^b   Kim, In San ^b   Byun, Youngro ^a   Kim, Sang Yoon ^c  

^a Seoul National University   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

^d Mediplex Corporation   (South Korea)

Author keywords

Angiogenesis; LMWH taurocholate conjugate; Polyproline type helical structure; Vascular endothelial growth factors 165 (VEGF165)

Indexed keywords

ANGIOGENESIS INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; LOW MOLECULAR WEIGHT HEPARIN PLUS TAUROCHOLIC ACID CONJUGATE; MATRIGEL; NADROPARIN; TAUROCHOLIC ACID; UNCLASSIFIED DRUG; VASCULOTROPIN 165; VASCULOTROPIN RECEPTOR 2; COLLAGEN; DRUG DERIVATIVE; HEPARIN; LAMININ; PEPTIDE; POLYPROLINE; PROTEOGLYCAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTICOAGULATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CIRCULAR DICHROISM; CONTROLLED STUDY; CRYSTAL STRUCTURE; DOSE RESPONSE; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; ISOTHERMAL TITRATION CALORIMETRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT; UMBILICAL VEIN; ANIMAL; C3H MOUSE; CELL CULTURE; CHEMISTRY; CYTOLOGY; DRUG COMBINATION; DRUG SCREENING; EXPERIMENTAL NEOPLASM; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHOSPHORYLATION; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CELLS, CULTURED; CIRCULAR DICHROISM; COLLAGEN; DRUG COMBINATIONS; ENDOTHELIUM, VASCULAR; HEPARIN; HUMANS; LAMININ; MALE; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED C3H; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDES; PHOSPHORYLATION; PROTEOGLYCANS; TAUROCHOLIC ACID; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 65649114685     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24239     Document Type: Article

References (36)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-1186
2. Brem S, Brem H, Folkman J, Finkelstein D, Patz A. Prolonged tumor dormancy by prevention of neovascularization in the vitreous. Cancer Res 1976;36:2807-2812
3. Parangi S, Dietrich W, Christofori G, Lander ES, Hanahan D. Tumor suppressor loci on mouse chromosomes 9 and 16 are lost at distinct stages of tumorigenesis in a transgenic model of islet cell carcinoma. Cancer Res 1995;55:6071-6076
4. Griffioen AW, Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases and chronic inflammation. Pharmacol Rev 2000;52:237-268 (Pubitemid 30368433)
5. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-257
6. Senger DR, Perruzzi CA, Feder J, Dvorak HF. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 1986;46:5629-5632 (Pubitemid 17177959)
7. Schmidt NO, Westphal M, Hagel C, Ergun S, Stavrou D, Rosen EM, Lamszus K. Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int J Cancer 1999;84:10-18. (Pubitemid 29059101)
8. Kumar R, Kuniyasu H, Bucana CD, Wilson MR, Fidler IJ. Spatial and temporal expression of angiogenic molecules during tumor growth and progression. Oncol Res 1998;10:301-311 (Pubitemid 128736327)
9. Smorenburg SM, Van Noorden CJ. The complex effects on heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev 2001;53:93-105. (Pubitemid 32173109)
10. Folkman J, Langer R, Linhardt RJ, Haudenschild C, Taylor S. Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science 1983;221:719-725
11. Schlessinger J, Lax I, Lemmon M. Regulation of growth factor activation by proteoglycans: what is the role of the low affinity receptors? Cell 1995;83:357-360
12. Soker S, Goldstaub D, Svahn CM, Vlodavsky I, Levi BZ, Neufeld G. Variations in the size and sulfation of heparin modulate the effect of heparin on the binding of VEGF165 to its receptors. Biochem Biophys Res Commun 1994;203:1339-1347 (Pubitemid 24304976)
13. Tessler S, Rockwell P, Hicklin D, Cohen T, Levi BZ, Witte L, Lemischka IR, Neufeld G. Heparin modulates the interaction of VEGF165 with soluble and cell associated flk-1 receptors. J Biol Chem 1994;269:12456-12461 (Pubitemid 24202025)
14. Jayson GC, Gallagher JT. Heparin oligosaccharides: inhibitors of the biological activity of bFGF on Caco-2 cells. Br J Cancer 1997;75:9-16. (Pubitemid 27007267)
15. Hirsh J. Heparin. N Engl J Med 1991;324:1565-1574
16. Jaques LB. Heparins: anionic polyelectrolyte drugs. Pharmacol Rev 1979;31:99-166.
17. Jin L, Abrahams JP, Skinner R, Petitou M, Pike RN, Carrell RW. The anticoagulant activation of antithrombin by heparin. Proc Natl Acad Sci USA 1997;94:14683-14688 (Pubitemid 28041434)
18. Hettiarachchi RJ, Smorenburg SM, Ginsberg J, Levine M, Prins MH, Buller HR. Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemostasis 1999;82:947-952
19. Thorpe PE, Derbyshire EJ, Andrade SP, Press N, Knowles PP, King S, Watson GJ, Yang YC, Rao-Bette M. Heparin-steroid conjugates: new angiogenesis inhibitors with antitumor activity in mice. Cancer Res 1993;53:3000-3007 (Pubitemid 23210303)
20. Park K, Lee GY, Kim YS, Yu M, Park RW, Kim IS, Kim SY, Byun Y. Heparin-deoxycholic acid chemical conjugate as an anticancer drug carrier and its antitumor activity. J Control Release 2006;114:300-306 (Pubitemid 44310810)
21. Park K, Kim YS, Lee GY, Nam JO, Lee SK, Park RW, Kim SY, Kim IS, Byun Y. Antiangiogenic effect of bile acid acylated heparin derivative. Pharm Res 2007;24:176-185 (Pubitemid 44902582)
22. Yu MK, Lee DY, Kim YS, Park K, Park SA, Son DH, Lee GY, Nam JH, Kim SY, Kim IS, Park RW, Byun Y. Antiangiogenic and apoptotic properties of a novel amphiphilic folate-heparin-lithocholate derivative having cellular internality for cancer therapy. Pharm Res 2007;24:705-714 (Pubitemid 46411960)
23. Pumphrey CY, Theus AM, Li S, Parrish RS, Sanderson RD. Neoglycans, carbodiimide-modified glycosaminoglycans: a new class of anticancer agents that inhibit cancer cell proliferation and induce apoptosis. Cancer Res 2002;62:3722-3728 (Pubitemid 34728853)
24. Eriksson S, Sjovall J. The absorption spectra of bile acids in sulfuric acid. Ark Kemi 1955;8:303-311
25. Nichifor M. Carpov A. Bile acids covalently bound to polysaccharides. I. Ester of bile acids with dextran. Eur Polym J 1999;35:2125-2129
26. Nichifor M, Stanciu MC, Zhu XX. Bile acids covalently bound to polysaccharides. II. Dextran with pendant cholic acid groups. React Funct Polym 2004;59:141-148
27. Rabanal F, Ludevid MD, Pons M, Giralt E. CD of proline-rich polypeptides: application to the study of the repetitive domain of maize glutelin-2. Biopolymers 1993;33:1019-1028 (Pubitemid 23184437)
28. Ma K, Kan L, Wang K. Polyproline II helix is a key structural motif of the elastic PEVK segment of titin. Biochemistry 2001;40:3427-3438 (Pubitemid 32242799)
29. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-676 (Pubitemid 36749215)
30. Cross RT, Sobel M, Marques D, Harris RB. Heparin binding domain peptides of antithrombin III: analysis by isothermal titration calorimetry and circular dichroism spectroscopy. Protein Sci 1994;3:620-627 (Pubitemid 24136367)
31. Robinson CJ, Mulloy B, Gallagher JT, Stringer SE. VEGF165-binding sites within heparan sulfate encompass two highly sulfated domains and can be liberated by K5 lyase. J Biol Chem 2006;281:1731-1740 (Pubitemid 43752490)
32. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-4599 (Pubitemid 27441066)
33. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-337
34. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Ioffe E, Huang T, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002;99:11393-11398 (Pubitemid 34920936)
35. Verheul H, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007;7:475-485 (Pubitemid 46809172)
36. Robert C, Faivre S, Raymond E, Armand JP, Escudier B. Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors. Ann Intern Med 2005;143:313-314 (Pubitemid 41134231)